Would switching from reference adalimumab to a biosimilar have any impact on disease activity or adverse effects among patients with inflammatory rheumatic joint diseases? Take our quiz to find out!
Patients with stable inflammatory rheumatic joint diseases experienced no signs of disease activity flare or adverse effects after switching from adalimumab reference Humira to adalimumab biosimilar Amgevita. True or false?
Rheumatology and Arthritis Learning Network® is an online resource for the latest developments in rheumatology practice, providing a customized experience for readers to stay informed about the topics that matter most to them.
Upadacitinib Shows Positive Results in Clinical Trials for AS, nr-axSpA
Late-Breaking Results from Phase 3 Trials of Risankizumab